AIDS TREATMENT NEWS #133, August 23, 1991
John S. James
Persons with moderate or severe molluscum contagiosum which has failed other treatments may be eligible for a clinical trial of low-dose alpha interferon (5 million units daily by subcutaneous injection). The trial is sponsored by the Community Consortium; volunteers will be seen at the Dermatology Clinic at San Francisco General Hospital, and will learn to inject themselves so they can take the medicine at home. The trial will last eight weeks. Any antiretroviral therapy (AZT, ddI, or ddC) is OK during the trial.
For more information, call Marcela Mirda, R. N., 415/476- 9554.
** The Positive Woman: Phone Number Correction; Washington, D. C., Meeting
In issue #130, AIDS TREATMENT NEWS published an incorrect phone number for The Positive Woman, a newsletter by and for HIV- positive women and their families and friends. The correct phone number is 202/898-0372.
Note: On Wednesday, August 28, The Positive Woman and other organizations will sponsor a report on the Seventh International Conference on AIDS, June 1991 in Florence. The meeting will be 6:30 to 8:30 p.m. at the Martin Luthor King Memorial Library in Washington, D. C. For more information, call The Positive Woman at the number above.
** Azithromycin Available
In the last issue of AIDS TREATMENT NEWS we said that we had not heard of buyers' club access for azithromycin, an experimental treatment for toxoplasmosis and also for MAC. Since then we have learned that the PWA Health Group in New York, 212/532-0280, can help people import the drug for personal use. As we said in the last issue, azithromycin is also available through a compassionate-use program from Pfizer Inc., its developer, for treatment of some cases of toxoplasmosis.
910823
ATN13303
Copyright © 1991 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .